Mobile

A study to assess the efficacy and safety of oral rigosertib in patients with myelodysplastic syndrome (a blood disease) who are dependent on transfusions

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-000672-15

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary efficacy objective is to determine the onset of hematological improvement according to the 2006 International Working Group (IWG) criteria.

Critère d'inclusion

  • myelodysplastic syndrome

Liens